These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

661 related items for PubMed ID: 20522841

  • 1. Efficacy of a new once-daily long-acting inhaled beta2-agonist indacaterol versus twice-daily formoterol in COPD.
    Dahl R, Chung KF, Buhl R, Magnussen H, Nonikov V, Jack D, Bleasdale P, Owen R, Higgins M, Kramer B, INVOLVE (INdacaterol: Value in COPD: Longer Term Validation of Efficacy and Safety) Study Investigators.
    Thorax; 2010 Jun; 65(6):473-9. PubMed ID: 20522841
    [Abstract] [Full Text] [Related]

  • 2. Effects of long-acting bronchodilators in COPD patients according to COPD severity and ICS use.
    Decramer M, Dahl R, Kornmann O, Korn S, Lawrence D, McBryan D.
    Respir Med; 2013 Feb; 107(2):223-32. PubMed ID: 23219347
    [Abstract] [Full Text] [Related]

  • 3. Bronchodilator effects of indacaterol and formoterol in patients with COPD.
    Beier J, Beeh KM, Brookman L, Peachey G, Hmissi A, Pascoe S.
    Pulm Pharmacol Ther; 2009 Dec; 22(6):492-6. PubMed ID: 19465142
    [Abstract] [Full Text] [Related]

  • 4. Efficacy and safety of once-daily QVA149 compared with the free combination of once-daily tiotropium plus twice-daily formoterol in patients with moderate-to-severe COPD (QUANTIFY): a randomised, non-inferiority study.
    Buhl R, Gessner C, Schuermann W, Foerster K, Sieder C, Hiltl S, Korn S.
    Thorax; 2015 Apr; 70(4):311-9. PubMed ID: 25677679
    [Abstract] [Full Text] [Related]

  • 5. Efficacy and tolerability of indacaterol 75 μg once daily in patients aged ≥40 years with chronic obstructive pulmonary disease: results from 2 double-blind, placebo-controlled 12-week studies.
    Kerwin EM, Gotfried MH, Lawrence D, Lassen C, Kramer B.
    Clin Ther; 2011 Dec; 33(12):1974-84. PubMed ID: 22177371
    [Abstract] [Full Text] [Related]

  • 6. 24-hour bronchodilator efficacy of single doses of indacaterol in subjects with COPD: comparison with placebo and formoterol.
    Bauwens O, Ninane V, Van de Maele B, Firth R, Dong F, Owen R, Higgins M.
    Curr Med Res Opin; 2009 Feb; 25(2):463-70. PubMed ID: 19192991
    [Abstract] [Full Text] [Related]

  • 7. Safety, tolerability and efficacy of indacaterol, a novel once-daily beta(2)-agonist, in patients with COPD: a 28-day randomised, placebo controlled clinical trial.
    Beier J, Chanez P, Martinot JB, Schreurs AJ, Tkácová R, Bao W, Jack D, Higgins M.
    Pulm Pharmacol Ther; 2007 Feb; 20(6):740-9. PubMed ID: 17088091
    [Abstract] [Full Text] [Related]

  • 8. Once-daily bronchodilators for chronic obstructive pulmonary disease: indacaterol versus tiotropium.
    Donohue JF, Fogarty C, Lötvall J, Mahler DA, Worth H, Yorgancioglu A, Iqbal A, Swales J, Owen R, Higgins M, Kramer B, INHANCE Study Investigators.
    Am J Respir Crit Care Med; 2010 Jul 15; 182(2):155-62. PubMed ID: 20463178
    [Abstract] [Full Text] [Related]

  • 9. Efficacy and safety of indacaterol 150 and 300 µg in chronic obstructive pulmonary disease patients from six Asian areas including Japan: a 12-week, placebo-controlled study.
    Kinoshita M, Lee SH, Hang LW, Ichinose M, Hosoe M, Okino N, Prasad N, Kramer B, Fukuchi Y, Indacaterol Asian COPD Study Investigators.
    Respirology; 2012 Feb 15; 17(2):379-89. PubMed ID: 22122202
    [Abstract] [Full Text] [Related]

  • 10. Profiling the bronchodilator effects of the novel ultra-long-acting β2-agonist indacaterol against established treatments in chronic obstructive pulmonary disease.
    Vogelmeier C, Magnussen H, LaForce C, Owen R, Kramer B.
    Ther Adv Respir Dis; 2011 Oct 15; 5(5):345-57. PubMed ID: 21719531
    [Abstract] [Full Text] [Related]

  • 11. Profiling the effects of indacaterol on dyspnoea and health status in patients with COPD.
    Jones PW, Mahler DA, Gale R, Owen R, Kramer B.
    Respir Med; 2011 Jun 15; 105(6):892-9. PubMed ID: 21397482
    [Abstract] [Full Text] [Related]

  • 12. [Indacaterol--a new hope for maximising bronchodilation?].
    Mihălţan F.
    Pneumologia; 2011 Jun 15; 60(1):21-5. PubMed ID: 21548196
    [Abstract] [Full Text] [Related]

  • 13. Chronic treatment with indacaterol and airway response to salbutamol in stable COPD.
    Cazzola M, Rogliani P, Ruggeri P, Segreti A, Proietto A, Picciolo S, Matera MG.
    Respir Med; 2013 Jun 15; 107(6):848-53. PubMed ID: 23490225
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Monotherapy with indacaterol once daily reduces the rate of exacerbations in patients with moderate-to-severe COPD: Post-hoc pooled analysis of 6 months data from three large phase III trials.
    Wedzicha JA, Buhl R, Lawrence D, Young D.
    Respir Med; 2015 Jan 15; 109(1):105-11. PubMed ID: 25433954
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Efficacy of indacaterol 75 μg once-daily on dyspnea and health status: results of two double-blind, placebo-controlled 12-week studies.
    Gotfried MH, Kerwin EM, Lawrence D, Lassen C, Kramer B.
    COPD; 2012 Dec 15; 9(6):629-36. PubMed ID: 23020650
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Integrating indacaterol dose selection in a clinical study in COPD using an adaptive seamless design.
    Barnes PJ, Pocock SJ, Magnussen H, Iqbal A, Kramer B, Higgins M, Lawrence D.
    Pulm Pharmacol Ther; 2010 Jun 15; 23(3):165-71. PubMed ID: 20080201
    [Abstract] [Full Text] [Related]

  • 20. Nebulized arformoterol in patients with COPD: a 12-week, multicenter, randomized, double-blind, double-dummy, placebo- and active-controlled trial.
    Baumgartner RA, Hanania NA, Calhoun WJ, Sahn SA, Sciarappa K, Hanrahan JP.
    Clin Ther; 2007 Feb 15; 29(2):261-78. PubMed ID: 17472819
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 34.